Affiliation:
1. AstraZeneca India Pvt. Ltd., Malleswaram, Bangalore 560003, India
Abstract
ABSTRACT
Limited information exists on the pharmacokinetic (PK)-pharmacodynamic (PD) relationships of drugs against
Mycobacterium tuberculosis
. Our aim was to identify the PK-PD parameter that best describes the efficacy of rifampin on the basis of in vitro and PK properties. Consistent with 83.8% protein binding by equilibrium dialysis, the rifampin MIC for
M. tuberculosis
strain H37Rv rose from 0.1 in a serum-free system to 1.0 mg/ml when it was tested in the presence of 50% serum. In time-kill studies, rifampin exhibited area under the concentration-time curve (AUC)-dependent killing in vitro, with maximal killing seen on all days and with the potency increasing steadily over a 9-day exposure period. MIC and time-kill studies performed with intracellular organisms in a macrophage monolayer model yielded similar results. By use of a murine aerosol infection model with dose ranging and dose fractionation over 6 days, the PD parameter that best correlated with a reduction in bacterial counts was found to be AUC/MIC (
r
2
= 0.95), whereas the maximum concentration in serum/MIC (
r
2
= 0.86) and the time that the concentration remained above the MIC (
r
2
= 0.44) showed lesser degrees of correlation.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
309 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献